香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容 而引致的任何損失承擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED ( 於香港註冊成立的有限公司 ) ( 股份代號： 2666) 董事名單及其角色與職能 通用環球醫療集團有限公司董事(「董事」)會(「董事會」)成員載列如下: 執行董事 非執行董事 童朝銀先生 林春海先生 黃友杰先生 馬萬銘先生 獨立非執行董事 鄒小磊先生 許志明先生 陳曉峰先生 1 陳仕俗先生 (主席) 夏 畦先生 (首席執行官) 王 琳女士 董事會已設立五個委員會，各委員會成員載列如下： 審核委員會 李引泉先生 (主席) 鄒小磊先生 童朝銀先生 李引泉先生 鄒小磊先生 (主席) 林春海先生 黃友杰先生 李引泉先生 許志明先生 提名委員會 陳仕俗先生 (主席) 王 琳女士 李引泉先生 鄒小磊先生 陳曉峰先生 戰略與ESG 委員會 陳仕俗先生 (主席) 黃友杰先生 馬萬銘先生 風險 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：2666） (1) 執行董事及首席執行官辭任；及 (2) 任命執行董事及首席執行官 董事會宣佈，以下內容自 2026 年 3 月 25 日起生效： 執行董事及首席執行官辭任 通用環球醫療集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，王文 兵先生（「王先生」）因其他工作安排，辭任執行董事、首席執行官及董事會風險控制委員 會（「風險控制委員會」）委員之職位，自 2026 年 3 月 25 日起生效。 王先生已確認其與董事會之間沒有任何意見分歧，且並不知悉任何有關其辭任之其他事宜須 知會本公司股東及香港聯合交易所有限公司（「聯交所」）。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港注冊成立的有限公司） 於本公告日期，除以上所披露者外，夏先生概無(i)與本公司任何董事、高級管理人員、主要 股東或 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任 。 建議修訂組織章程細則須待本公司股東（「股東」）於本公司即將舉行之股東週年大會 （「股東週年大會」）上通過特別決議案批准採納後方可作實。一份載有（其中包括） 建議修訂之詳情及股東週年大會通告之通函將於適當時候寄發予股東。 承董事會命 通用環球醫療集團有限公司 Genertec Universal Medical Group Company Limited 陳仕俗 董事會主席 中國北京，二零二六年三月二十五日 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED ( 於香港註冊成立的有限公司) ( 股份代號： 2666) 建議修訂組織章程細則 通用環球醫療集團有限公司（「本公司」）董事會（「董事會」）建議對本公司組織章程 細則（「組織章程細則」）作出修訂，使其與 (i) 修訂後的公司條例（香港法例第622章） 有關在香港註冊成立的上市公司實施庫存股份制度以及推動 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 通用環球醫療集團有限公司 | | 股份代號 | 02666 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年十二月三十一日止年度的末期股息 | | 公告日期 | 2026年3月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.36 HKD | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.36 HKD | | 匯率 | 1 HKD : 1 HKD ...

Financial Performance - For the year ended December 31, 2025, revenue was approximately RMB 14,939.5 million, an increase of 9.3% compared to RMB 13,663.5 million in 2024[2] - The healthcare business revenue reached approximately RMB 9,901.8 million, growing by 16.7% year-over-year, accounting for 66.3% of total revenue[2] - Net profit for the year was approximately RMB 2,317.6 million, a 2.6% increase from RMB 2,258.3 million in 2024[2] - The company reported a basic earnings per share of RMB 1.13, compared to RMB 1.07 in 2024[3] - The total comprehensive income for the year is RMB 2,226,872 thousand, reflecting a solid performance amidst market challenges[8] - The company’s total comprehensive income for the year includes a profit of RMB 2,354,255 thousand, up from RMB 2,133,155 thousand in the previous year, marking an increase of approximately 10.34%[9] - The company reported a net profit of RMB 2,258,334 thousand for the year, compared to RMB 1,747,632 thousand in the previous year, reflecting a growth of 29.2%[41] - The pre-tax profit for 2025 was RMB 3,019,148 thousand, compared to RMB 2,907,119 thousand in 2024, indicating a growth of about 3.8%[61] Assets and Liabilities - Total assets as of December 31, 2025, were approximately RMB 84,317.7 million, a decrease of 2.0% from RMB 86,032.3 million in 2024[2] - The total liabilities decreased by RMB 1,256,423 in 2025, contrasting with an increase of RMB 2,250,346 in 2024, indicating a positive trend in debt management[11] - The company’s total liabilities for 2025 stand at RMB 7,882,256 thousand, down from RMB 8,124,715 thousand in 2024, indicating a reduction of 3.0%[109] - The total amount of interest-bearing assets as of December 31, 2025, was RMB 69,614,189 thousand, with a total impairment provision of RMB 2,340,614 thousand[94] - The total liabilities as of December 31, 2025, were RMB 59,278,687 thousand, down from RMB 63,162,550 thousand in 2024, indicating a reduction of approximately 6.0%[159] Equity and Shareholder Information - The equity attributable to ordinary shareholders was approximately RMB 2,156.8 million, up 6.2% from RMB 2,031.7 million in 2024[2] - The total equity as of December 31, 2025, is RMB 25,038,977 thousand, an increase from RMB 22,869,745 thousand in 2024, reflecting a growth of approximately 9.5%[8] - The company reported a total of RMB 2,156,763 thousand in profit attributable to ordinary shareholders for 2025, compared to RMB 2,031,740 thousand in 2024, reflecting an increase of approximately 6.2%[64] - The proposed final dividend for 2025 is HKD 0.36 per share, an increase from HKD 0.35 per share in 2024, reflecting a growth of about 2.9%[63] Cash Flow and Financing Activities - The net cash flow from operating activities for the year 2025 is RMB 5,654,096 thousand, slightly down from RMB 5,660,742 thousand in 2024[10] - The company reported a net cash outflow from investing activities of RMB 958,753 in 2025, compared to RMB 1,084,963 in 2024, indicating a reduction in investment cash outflows[12] - The company experienced a decrease in cash and cash equivalents by RMB 276,872 in 2025, compared to a decrease of RMB 467,325 in 2024, showing an improvement in cash management[12] - The company recorded a significant increase in cash flow from financing activities, with a net outflow of RMB 5,094,451 in 2025, compared to RMB 520,670 in 2024, highlighting a shift in financing strategy[12] Operational Performance - The company operated 67 medical institutions, with a total of 15,628 beds, generating RMB 8,182.6 million in revenue from the integrated medical segment, a 7.5% increase year-on-year[164] - The total number of patient visits across 65 consolidated medical institutions was approximately 10.616 million, reflecting a 1.9% year-on-year growth[165] - The average revenue per bed was approximately RMB 490,000, with top-tier hospitals achieving around RMB 670,000 per bed[165] - The company registered over 6 million users on its unified internet platform, serving a total of over 50 million people[167] - The company aims to maintain a bed occupancy rate of around 90% and has optimized the average length of stay to 9.4 days[167] Investment and Growth Strategy - The company plans to continue expanding its market presence and is focusing on new product development to drive future growth[8] - The company aims to enhance its capabilities through both organic growth and strategic acquisitions, focusing on high-end medical equipment and lifecycle management[178] - The group plans to establish 15 standardized national medical centers and 3 national-level renowned traditional Chinese medicine studios by 2025, having completed 30 standardized national medical centers to date[172] - The group is committed to building a first-class ophthalmology industry platform, having successfully acquired Shandong University of Traditional Chinese Medicine Affiliated Eye Hospital as its flagship hospital[172] Risk Management and Compliance - The company has allocated RMB 67,986 thousand to general risk reserves, indicating a proactive approach to risk management[8] - The group has adopted the revised Hong Kong Financial Reporting Standards effective from January 1, 2025, with no significant impact on the financial statements for the current and prior periods[18] - The group anticipates that the application of new standards will not have a significant effect on its performance and financial position[21] - The company utilizes a provision matrix for impairment analysis to measure expected credit losses, incorporating forward-looking information and various assumptions[95] Market and Industry Trends - The financing leasing industry in China is undergoing a structural transformation, with significant potential for long-term growth due to low penetration rates compared to developed markets[183] - The company is actively developing a new model of "financing leasing + full life cycle management" in the medical equipment sector[184] - The health technology business generated revenue of RMB 1,487.0 million in 2025, up RMB 639.7 million or 75.5% year-on-year[199] - The group is enhancing its core competitiveness in health technology and aims to build a comprehensive health industry ecosystem[199]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 GENERTE CUNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 持續關連交易 超出年度上限 茲提述本公司日期為 2023年11月23日及2025年10月28日之公告（「该等公告」），内容 有關（其中包括）2024年醫療相關產品採購框架協議進行之持續關連交易，以及其項下之 年度上限及經修訂年度上限。除文義另有所指外，本公告所用詞彙與該等公告所界定者具 有相同涵義。 超出年度上限 於釐定本集團截至2025年12月31日止年度之全年業績過程中，本公司發現根據2024年醫療 相關產品採購框架協議進行之持續關連交易，已超出截至2025年12月31日止年度之年度上 限。根據本公司財務資料，於2025年12月31日，本集團向通用技術集團及／或其聯繫人實 際發生之總金額為人民幣5.478338 億元，超出本公司先前設定之人民幣3.6 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事會會議召開日期 通用環球醫療集團有限公司 (「本公司」，連同其附屬公司為「本集團」) 董事會(「董 事會」) 謹此宣佈，本公司將於二零二六年三月二十五日（星期三）舉行董事會會議， 藉以（其中包括）考慮及批准本集團截至二零二五年十二月三十一日止年度的全年業 績及其發佈，並考慮建議派付之末期股息(如有)，以及處理其他事項。 承董事會命 通用環球醫療集團有限公司 Genertec Universal Medical Group Company Limited 陳仕俗 董事會主席 中國北京，二零二六年三月十日 於本公告日期，本公司的執行董事為陳仕俗先生（主席）、王文兵先生及王琳女士；本公司的 非執行董事為童朝銀先生、林春海先生、黃友杰先生及馬萬銘先生；而本公司的獨立非執行董 事為李引泉先生、鄒小磊先生、許志明先生及陳曉峰先生。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年2月28日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 通用環球醫療集團有限公司 | | | 呈交日期: | 2026年3月5日 | | | I. 法定/註冊股本變動 不適用 | | | | 備註： | | | | 因公司註冊成立於香港，故法定股本及註冊股本的概念並不適用。 | | | FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 02666 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 2,014,204,924 0 2,014,204,924 增加 / 減少 (-) 本月底結存 2,014,204,924 0 2,014,204,924 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D ...

Group 1 - Southbound funds reduced their holdings in Universal Medical (02666.HK) by 405,500 shares on February 27 [1] - Over the past five trading days, southbound funds have increased their holdings for four days, with a total net increase of 3,909,000 shares [1] - In the last 20 trading days, there have been 16 days of net increases in holdings by southbound funds, totaling 14,459,500 shares [1] Group 2 - As of now, southbound funds hold 456 million shares of Universal Medical, accounting for 22.63% of the company's issued ordinary shares [1] - Universal Medical Group Limited (formerly known as Universal Medical Financial and Technical Consulting Services Limited) is a Chinese company engaged in the healthcare business [1] - The company operates mainly through two segments: financial services, which include direct financing leasing, sale-leaseback, insurance, operating leasing, and consulting services; and healthcare services, which encompass medical health services, hospital operation management, and medical equipment import and export trade [1]

Group 1 - The core viewpoint of the article highlights that southbound funds have increased their holdings in Universal Medical (02666.HK) by 1.712 million shares on February 23, with a total net increase of 4.797 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have increased their holdings on 16 occasions, resulting in a cumulative net increase of 14.1665 million shares [1] - As of now, southbound funds hold 456 million shares of Universal Medical, accounting for 22.64% of the company's total issued ordinary shares [1] Group 2 - Universal Medical Group Limited, formerly known as Universal Medical Financial and Technical Consulting Services Limited, is a Chinese company engaged in the healthcare business [1] - The company operates mainly through two segments: the financial services segment, which includes direct financing leasing, sale-leaseback, insurance, operating leasing, and consulting services; and the healthcare segment, which encompasses healthcare services, hospital operation management, medical equipment import and export trade, domestic trade, full-cycle equipment management, and medical digital technology services [1] - The company's operations are primarily conducted within mainland China [1]